Quebec News Tribune – Lifestyle
Author:
Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
April 21, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026